ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

摘要:

The results of the National Institute of Neurological Diseases and Stroke (NINDS) trial represent a real breakthrough, demonstrating that thrombolytic therapy with intravenous alteplase [t-PA, ‘Activase’; Genentech] is an effective treatment for acute ischacmic stroke.*While this approach does have risks, it means that ischaemic stroke can be treated as the life-threatening disease that it is. Investigators discussed the ‘real world approach’ to patient selection for thrombolysis and pre- and post-stroke management with alteplase for acute ischaemic stroke, at the 49th Annual Meeting of the American Academy of Neurology [Boston, US; April 1997].

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

摘要:

Edobacomab [E5] is the latest victim in a long line of agents that have failed to show efficacy in pivotal trials of sepsis. However, leading experts in endotoxin research still believe that targeting lipopolysaccharide (LPS) holds considerable promise as a therapeutic option in this indication. The latest results from studies involving rBPI21[recombinant bactericidal/permeability-increasing protein, ‘Neuprex’] support this view. Good results have been seen in studies of this agent that have involved highly defined, endotoxin-related indications. The latest data on both edobacomab and rBPI21were presented at the 7th International IBC Conference on Sepsis [Washington DC, US; April 1997]. Other approaches to neutralising the effects of bacterial endotoxins will be discussed in a future issue ofInpharma.

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS